33 news items
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
ABBV
AZN
BMY
19 Jun 24
cohort 5 abstract and poster detail a study assessing innovative treatments for patients newly diagnosed with metastatic PDAC. Utilizing
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
ABBV
AZN
BMY
19 Jun 24
cohort 5 abstract and poster detail a study assessing innovative treatments for patients newly diagnosed with metastatic PDAC
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
BMY
18 Jun 24
known and respected for its long history of innovation and scientific discovery. It's an exciting time at Bristol Myers Squibb and I look forward
U.S. Food and Drug Administration Approves Augtyroâ„¢ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY
13 Jun 24
longstanding legacy of bringing innovations to individuals who are facing cancer and urgently seeking new treatment options
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
BMY
EVO
12 Jun 24
partnership with Bristol Myers Squibb and our shared commitment to innovation and patient care. Together with Bristol Myers Squibb we have been able to advance
g0yilmazr0igs orvfb7zi77ivmnmwkf3fdsijgnb3t9lxjg6xro3
BMY
4 Jun 24
in personalized medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding
2i5zs9j6vsnajjr bri
BMY
3 Jun 24
with demonstrated improved outcomes, and we remain dedicated to leading the advancement of innovative therapies to improve outcomes for a wide range
6qoj3azk272efc5w3qi2d2 sgm0z4trhm8yuqsa8hozyt425ngjr
BMY
3 Jun 24
Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights
vxla4ctxtu2hnyh ub2x25b8ky5ctfyyjd9t6mhon
BMY
1 Jun 24
, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data
cnwl9bw 9ho3dpp43
BMY
30 May 24
changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative
6to1qcfngdlwgqs9oy81do
BMY
23 May 24
, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data
etkrb7sr p6
BMY
22 May 24
Squibb, an innovator in the immuno-oncology space, join our oversubscribed Series B extension round. The funding strengthens NeoPhore's position
zhi1bt0r32xg e9jy1u44hbr
BMY
21 May 24
is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases
6q2pjfnv1hxef597jolgxx4vbm44w7k374f5pja2
BMY
16 May 24
development, Immunology, Cardiovascular and Neuroscience, Bristol Myers Squibb. "Our leadership in TYK2 innovation highlights our transformational science
k7tp0s3js3wwvuimwzdfdy4heumw6d7y6dfewqxy0ja4weo
BMY
15 May 24
innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge
l8qj3xtrdjy0wzz2wwtjrpzf5s7cpwsk fp4uhk2zxwzf1
BMY
CATX
LNTH
15 May 24
of developing potential innovative precision medicines based on alpha-emitting isotopes and peptide optimization. In the coming months, we look forward
rg2pvfjbp4z76hlpyc04vg4v8sxrylu6s7nw9jfxi5exohgl2ca3 7b3228
BMY
10 May 24
Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights
7ff5p7msu2ne
BMY
ENOV
7 May 24
and reinforces our ability to innovate and take incremental market share in the global orthopedic market. The integration is progressing according to plan
zpad90f215ic9h9vxspbxoe gg9bnds5qt
BMY
30 Apr 24
collaborators in crafting innovative medicines for patients with devastating conditions
vri6ut3nvedtos994i06n1enz290
BMY
29 Apr 24
-leading expertise in developing and commercializing innovative immune medicines